Biocept Inc says its CNSide assay identified HER2 and other actionable tumor alterations in the cerebrospinal fluid of patients with breast cancer and leptomeningeal disease
A poster of the study demonstrating the ability of CNSide was chosen for a Spotlight Presentation at the San Antonio Breast Cancer Symposium...